Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small Cajal body-specific RNA 8 (SCARNA8, also known as U92) is a small, non-coding, H/ACA box RNA that localizes to Cajal bodies within the nucleus. Its primary function is to guide the site-specific pseudouridylation (conversion of uridine to pseudouridine) of U2 spliceosomal RNA at a defined nucleotide position by forming an RNA-protein complex with associated factors such as GAR1. SCARNA8 is part of a broader class called scaRNAs, which are vital for the maturation and chemical modification of spliceosomal snRNAs (including U1, U2, U4, U5, and U12), thus ensuring proper splicing of pre-mRNA. Although scaRNAs are essential for cellular RNA processing and spliceosome function, SCARNA8 itself is not a therapeutic target and has no direct links to disease mechanisms or drug actions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small Cajal body-specific RNA 8 (SCARNA8).